News & Blog

Meet the Community – Duncan Collins

Larimar Therapeutics Receives FDA Clearance

Larimar Therapeutics Receives FDA Clearance to Proceed to 50 mg Cohort in CTI-1601’s Phase 2 Friedreich’s Ataxia Trial and to Initiate Open Label Extension Trial

Meet the Community – Kiara Lynch–Owen

Meet the Community – Tricia Herman-Maul

Meet the Community 2: A Closer Look – Abby G

Lexeo Therapeutics Announces Completion of First Cohort and Dosing in Second Cohort in SUNRISE-FA, a Phase 1/2 Clinical Trial of LX2006 for the Treatment of Friedreich’s Ataxia Cardiomyopathy

FARA Celebrates the 15th Annual Ataxian Athlete Initiative (AAI) for People with Ataxia

May 2023 – Advocacy Newsletters

Meet the Community – Vezirka Bećić

PTC Therapeutics Announces Topline Results from Vatiquinone MOVE-FA Registration-Directed Trial

Larimar Therapeutics Reports Preliminary Top-line Data from Phase 2 Trial’s 25 mg Cohort – First Quarter 2023 Financial Results